Description
What does it take to thrive in today's competitive and ever-evolving entrepreneurial landscape? In this episode, I'm joined by Mario Peshev, CEO of DevriX and author of the new book "MBA Disrupted." Mario will share practical insights from his extensive experience as an entrepreneur and the framework he has developed for digital entrepreneurship success. From navigating economic downturns to leveraging AI tools for business efficiency, Mario's advice is not just theoretical, but actionable for aspiring and seasoned entrepreneurs alike.
We'll begin by exploring the current landscape of entrepreneurship. Mario will discuss the increased opportunities and heightened competition in the market, emphasizing the importance of perseverance, hard work, and adopting a CEO mindset. He'll also highlight why second-time entrepreneurs often see more success and the critical role of thorough research and preparation in avoiding failure.
As we delve into the economic factors affecting businesses in 2024, Mario will provide a realistic view of entrepreneurs' challenges, such as stricter funding environments, longer sales cycles, and cost-cutting measures. He'll offer strategies to adjust expectations and capitalize on hiring opportunities arising from industry layoffs. Mario will stress the importance of understanding economic cycles, a key factor in successful business adaptation.
We'll then focus on how businesses can make the most of events like Prime Day and the upcoming holiday shopping season. Mario will explain why, despite the significant revenue generated, these events may have a small impact on some business models, especially in the B2B and B2C sectors.
In this episode of Tech Talks Daily, I enjoy a conversation with Rebecca Wooters, the Chief Digital Officer at Signet Jewelers, the world’s largest diamond retailer.
With renowned brands like Kay, Zales, Jared, and James Allen under its umbrella, Signet is revolutionizing the jewelry industry...
Published 09/07/24
In this episode, I have an insightful conversation with Chris Hart, the CEO of Creyon Bio, to dive into how artificial intelligence is reshaping drug development.
Creyon Bio is pioneering the use of AI to engineer Oligonucleotide-Based Medicines (OBMs), prioritizing safety in their approach to...
Published 09/06/24